Results 71 to 80 of about 7,224 (167)

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

Gastrointestinal Disorders
Introduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck, Nishaanth Dalavaye, Kalaikshiga Kengadaran, Mosammath Monira Khatun, Ria Hitesh Patel, Taif Al-Rubaye, Laith Alrubaiy   +6 more
doaj   +1 more source

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service

AIDS Research and Therapy, 2019
Background Tenofovir disoproxil fumarate (TDF) is widely used in the management of HIV-infection, but has been associated with renal impairment in a small proportion of patients.
Dane Turner, Douglas Drak, Catherine C. O’Connor, David J. Templeton, David M. Gracey   +4 more
doaj   +1 more source

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Journal of Virus Eradication, 2018
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill, Sophie L. Hughes, Dzintars Gotham, Anton L. Pozniak   +3 more
doaj   +1 more source

Tenofovir alafenamide revisited.

Le infezioni in medicina, 2021
Two Tenofovir pro-drugs are available for the treatment of HIV and HBV infection. Tenofovir Alafenamide (TAF) was clinically developed as a safer alternative to the older Tenofovir Disoproxil Fumarate (TDF) as the latter was consistently found to be associated to proximal renal tubule dysfunction and decrease in bone mineral density (BMD).
openaire   +1 more source

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin. [PDF]

Clin Infect Dis
Osuala EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, Perumal R, Rooney JF, Wiesner L, Wasmann RE, Denti P, Dooley KE, Naidoo A, INSIGHT Study Team.   +11 more
europepmc   +1 more source

Tenofovir alafenamide/tenofovir disoproxil fumarate

Reactions Weekly, 2021
openaire   +1 more source

Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. [PDF]

Neurol Neuroimmunol Neuroinflamm
Torkildsen Ø, Bru ANS, Behzadi GIN, Myhr KM.   +3 more
europepmc   +1 more source

Population pharmacokinetics of tenofovir alafenamide delivered via an annual subdermal implant in South African women. [PDF]

Sci Rep
Beliveau M, Chang C, Lewis L, Letsoalo MP, Karim QA, Karim SSA, Marzinke MA, Moss JA, Gengiah TN, Baum MM.   +9 more
europepmc   +1 more source

Comparative Renal Safety of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A Korean Nationwide Study. [PDF]

J Korean Med Sci
Lim J, Yang J, Kim YJ, Kim HJ, Choi J.
europepmc   +1 more source

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED. [PDF]

J Acquir Immune Defic Syndr
Nguyen T, Chae JW, Ziemba L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD, IMPAACT 2010/VESTED Protocol Team.   +25 more
europepmc   +1 more source